UK Markets open in 6 hrs 34 mins

Global Pharmacovigilance Market to Reach $11.8 Billion by 2027

·25-min read

Abstract: - Global Pharmacovigilance Market to Reach $11. 8 Billion by 2027. - Amid the COVID-19 crisis, the global market for Pharmacovigilance estimated at US$5. 4 Billion in the year 2020, is projected to reach a revised size of US$11.

New York, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Pharmacovigilance Industry" - https://www.reportlinker.com/p06032498/?utm_source=GNW
8 Billion by 2027, growing at aCAGR of 11.9% over the period 2020-2027. Contract Outsourcing, one of the segments analyzed in the report, is projected to record 13.1% CAGR and reach US$7.6 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the In-House segment is readjusted to a revised 10% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $1.4 Billion, While China is Forecast to Grow at 15.7% CAGR
- The Pharmacovigilance market in the U.S. is estimated at US$1.4 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2027 trailing a CAGR of 15.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.3% and 10.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.

- Select Competitors (Total 42 Featured) -

  • Accenture

  • ArisGlobal

  • BioClinica Inc.

  • Capgemini

  • Cognizant

  • FMD K&L

  • IBM Corporation

  • ICON Plc

  • IQVIA

  • ITClinical

  • Laboratory Corporation of America Holdings

  • Linical Accelovance

  • Parexel International Corporation

  • TAKE Solutions Ltd.

  • United BioSource Corporation

  • Wipro Ltd.




Read the full report: https://www.reportlinker.com/p06032498/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Pharmacovigilance
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 2: World Historic Review for Pharmacovigilance by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Pharmacovigilance by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Contract
Outsourcing by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Contract Outsourcing by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Contract Outsourcing by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for In-House by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 8: World Historic Review for In-House by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 9: World 15-Year Perspective for In-House by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Cardiology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 11: World Historic Review for Cardiology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Cardiology by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Respiratory
Systems by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Respiratory Systems by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Respiratory Systems by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Other Therapeutic
Areas by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 17: World Historic Review for Other Therapeutic Areas by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Other Therapeutic Areas
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Oncology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 20: World Historic Review for Oncology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 21: World 15-Year Perspective for Oncology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Neurology by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Neurology by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 24: World 15-Year Perspective for Neurology by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Pharma Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 26: World Historic Review for Pharma Companies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Pharma Companies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Biotech Companies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 29: World Historic Review for Biotech Companies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 30: World 15-Year Perspective for Biotech Companies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Medical Device
Manufacturers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 32: World Historic Review for Medical Device
Manufacturers by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 33: World 15-Year Perspective for Medical Device
Manufacturers by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa for Years
2012, 2020 & 2027

Table 34: World Current & Future Analysis for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 35: World Historic Review for Other End-Uses by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Other End-Uses by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Spontaneous
Reporting by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 38: World Historic Review for Spontaneous Reporting by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 39: World 15-Year Perspective for Spontaneous Reporting
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Intensified ADR
Reporting by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 41: World Historic Review for Intensified ADR Reporting
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 42: World 15-Year Perspective for Intensified ADR
Reporting by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 43: World Current & Future Analysis for Targeted
Spontaneous Reporting by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific, Latin America, Middle East
and Africa Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2020 through 2027 and % CAGR

Table 44: World Historic Review for Targeted Spontaneous
Reporting by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 45: World 15-Year Perspective for Targeted Spontaneous
Reporting by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific,
Latin America, Middle East and Africa for Years 2012, 2020 &
2027

Table 46: World Current & Future Analysis for Cohort Event
Monitoring by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific, Latin America, Middle East and Africa
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2020 through 2027 and % CAGR

Table 47: World Historic Review for Cohort Event Monitoring by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 48: World 15-Year Perspective for Cohort Event Monitoring
by Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

Table 49: World Current & Future Analysis for EHR Mining by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific, Latin America, Middle East and Africa Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 50: World Historic Review for EHR Mining by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin
America, Middle East and Africa Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 51: World 15-Year Perspective for EHR Mining by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America,
Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 52: USA Current & Future Analysis for Pharmacovigilance
by Service Provider - Contract Outsourcing and In-House -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 53: USA Historic Review for Pharmacovigilance by Service
Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 54: USA 15-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2012, 2020 &
2027

Table 55: USA Current & Future Analysis for Pharmacovigilance
by Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 56: USA Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 57: USA 15-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2012, 2020 & 2027

Table 58: USA Current & Future Analysis for Pharmacovigilance
by End-Use - Pharma Companies, Biotech Companies, Medical
Device Manufacturers and Other End-Uses - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 59: USA Historic Review for Pharmacovigilance by End-Use -
Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 60: USA 15-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 61: USA Current & Future Analysis for Pharmacovigilance
by Type - Spontaneous Reporting, Intensified ADR Reporting,
Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR
Mining - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 62: USA Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 63: USA 15-Year Perspective for Pharmacovigilance by Type -
Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2012, 2020 & 2027

CANADA
Table 64: Canada Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 65: Canada Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 66: Canada 15-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2012, 2020 &
2027

Table 67: Canada Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 68: Canada Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 69: Canada 15-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2012, 2020 & 2027

Table 70: Canada Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 71: Canada Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 72: Canada 15-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 73: Canada Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 74: Canada Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 75: Canada 15-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2012, 2020 & 2027

JAPAN
Table 76: Japan Current & Future Analysis for Pharmacovigilance
by Service Provider - Contract Outsourcing and In-House -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 77: Japan Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 78: Japan 15-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2012, 2020 &
2027

Table 79: Japan Current & Future Analysis for Pharmacovigilance
by Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 80: Japan Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 81: Japan 15-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2012, 2020 & 2027

Table 82: Japan Current & Future Analysis for Pharmacovigilance
by End-Use - Pharma Companies, Biotech Companies, Medical
Device Manufacturers and Other End-Uses - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 83: Japan Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 84: Japan 15-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 85: Japan Current & Future Analysis for Pharmacovigilance
by Type - Spontaneous Reporting, Intensified ADR Reporting,
Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR
Mining - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 86: Japan Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 87: Japan 15-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2012, 2020 & 2027

CHINA
Table 88: China Current & Future Analysis for Pharmacovigilance
by Service Provider - Contract Outsourcing and In-House -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 89: China Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 90: China 15-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2012, 2020 &
2027

Table 91: China Current & Future Analysis for Pharmacovigilance
by Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology - Independent
Analysis of Annual Sales in US$ Million for the Years 2020
through 2027 and % CAGR

Table 92: China Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 93: China 15-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2012, 2020 & 2027

Table 94: China Current & Future Analysis for Pharmacovigilance
by End-Use - Pharma Companies, Biotech Companies, Medical
Device Manufacturers and Other End-Uses - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 95: China Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 96: China 15-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 97: China Current & Future Analysis for Pharmacovigilance
by Type - Spontaneous Reporting, Intensified ADR Reporting,
Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR
Mining - Independent Analysis of Annual Sales in US$ Million
for the Years 2020 through 2027 and % CAGR

Table 98: China Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 99: China 15-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2012, 2020 & 2027

EUROPE
Table 100: Europe Current & Future Analysis for
Pharmacovigilance by Geographic Region - France, Germany,
Italy, UK, Spain, Russia and Rest of Europe Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 101: Europe Historic Review for Pharmacovigilance by
Geographic Region - France, Germany, Italy, UK, Spain, Russia
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 102: Europe 15-Year Perspective for Pharmacovigilance by
Geographic Region - Percentage Breakdown of Value Sales for
France, Germany, Italy, UK, Spain, Russia and Rest of Europe
Markets for Years 2012, 2020 & 2027

Table 103: Europe Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 104: Europe Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 105: Europe 15-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2012, 2020 &
2027

Table 106: Europe Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 107: Europe Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 108: Europe 15-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2012, 2020 & 2027

Table 109: Europe Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 110: Europe Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 111: Europe 15-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 112: Europe Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 113: Europe Historic Review for Pharmacovigilance by Type -
Spontaneous Reporting, Intensified ADR Reporting, Targeted
Spontaneous Reporting, Cohort Event Monitoring and EHR Mining
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 114: Europe 15-Year Perspective for Pharmacovigilance by
Type - Percentage Breakdown of Value Sales for Spontaneous
Reporting, Intensified ADR Reporting, Targeted Spontaneous
Reporting, Cohort Event Monitoring and EHR Mining for the Years
2012, 2020 & 2027

FRANCE
Table 115: France Current & Future Analysis for
Pharmacovigilance by Service Provider - Contract Outsourcing
and In-House - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 116: France Historic Review for Pharmacovigilance by
Service Provider - Contract Outsourcing and In-House Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 117: France 15-Year Perspective for Pharmacovigilance by
Service Provider - Percentage Breakdown of Value Sales for
Contract Outsourcing and In-House for the Years 2012, 2020 &
2027

Table 118: France Current & Future Analysis for
Pharmacovigilance by Therapeutic Area - Cardiology, Respiratory
Systems, Other Therapeutic Areas, Oncology and Neurology -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 119: France Historic Review for Pharmacovigilance by
Therapeutic Area - Cardiology, Respiratory Systems, Other
Therapeutic Areas, Oncology and Neurology Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 120: France 15-Year Perspective for Pharmacovigilance by
Therapeutic Area - Percentage Breakdown of Value Sales for
Cardiology, Respiratory Systems, Other Therapeutic Areas,
Oncology and Neurology for the Years 2012, 2020 & 2027

Table 121: France Current & Future Analysis for
Pharmacovigilance by End-Use - Pharma Companies, Biotech
Companies, Medical Device Manufacturers and Other End-Uses -
Independent Analysis of Annual Sales in US$ Million for the
Years 2020 through 2027 and % CAGR

Table 122: France Historic Review for Pharmacovigilance by
End-Use - Pharma Companies, Biotech Companies, Medical Device
Manufacturers and Other End-Uses Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 123: France 15-Year Perspective for Pharmacovigilance by
End-Use - Percentage Breakdown of Value Sales for Pharma
Companies, Biotech Companies, Medical Device Manufacturers and
Other End-Uses for the Years 2012, 2020 & 2027

Table 124: France Current & Future Analysis for
Pharmacovigilance by Type - Spontaneous Reporting, Intensified
ADR Reporting, Targeted Spontaneous Reporting, Cohort Event
Monitoring and EHR Mining - Independent Analysis of Annual
Sales in US$ Million for the Years 2020 through 2027 and % CAGR

Table 125: France Historic Review for Pharmacovigilance by Type -

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06032498/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting